Company news
Pavmed Inc. (NASDAQ:PAVM) news
Pavmed Inc. news releases on 6ix. Latest, Aug 2, 2021: CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
Press releases — page 3
CORRECTING and REPLACING PAVmed to Hold Business Update Conference Call on August 12, 2021
August 1, 2021
PAVmed Subsidiary Lucid Diagnostics Launches Strategic Partnership with Direct-to-Consumer Telemedicine Company UpScriptHealth
July 21, 2021
PAVmed Subsidiary Lucid Diagnostics Completes European CE Mark Certification of its EsoGuard Esophageal DNA Test
June 9, 2021
PAVmed Launches Digital Health Company Veris Health Inc.
June 1, 2021
PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device
May 25, 2021
PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device
May 24, 2021
PAVmed Provides Business Update and First Quarter 2021 Financial Results
May 16, 2021
PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
May 12, 2021
PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team
May 5, 2021
PAVmed to Hold Business Update Conference Call on May 17, 2021
May 2, 2021
Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors
April 28, 2021
Global Industry Executive Debbie White Joins PAVmed Board of Directors
April 26, 2021
PAVmed Retires Convertible Debt
March 2, 2021
PAVmed Announces Closing of its Public Offering of Common Stock
February 24, 2021
PAVmed Announces Pricing of $45 Million Public Offering of Common Stock
February 22, 2021
PAVmed Announces Proposed Public Offering of Common Stock
February 21, 2021
PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST
February 17, 2021
First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed’s CarpX® Device
February 15, 2021
PAVmed to Hold Business Update Conference Call on February 22, 2021
February 8, 2021
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 7, 2021
PAVmed Announces Registered Direct Offering of its Common Stock Priced At-the-Market under Nasdaq Rules
January 5, 2021
PAVmed Closes Additional $8.1 Million Common Stock Registered Direct Offering
December 21, 2020
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
December 17, 2020
PAVmed Announces Registered Direct Offering of its Common Stock
December 10, 2020
PAVmed Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020
PAVmed to Hold Business Update Conference Call on November 17, 2020
November 1, 2020
PAVmed Reports Second Quarter 2020 Financial Results and Provides Business Update
August 17, 2020
PAVmed Secures $7 Million Convertible Note Financing
August 5, 2020
PAVmed to Hold Business Update Conference Call on August 18, 2020
July 27, 2020
PAVmed to Join the Russell 2000® and Russell 3000® Indexes
June 16, 2020
PAVmed Collaborates with Canon on DisappEAR™ Pediatric Ear Tubes
June 2, 2020
PAVmed Reports Preliminary First Quarter 2020 Financial Results and Provides Business Update
May 20, 2020
PAVmed to Hold Business Update Conference Call on May 21, 2020
May 10, 2020
PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device
April 20, 2020
PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update
April 8, 2020
PAVmed to Hold Business Update Conference Call on April 9, 2020
March 23, 2020
PAVmed Announces FDA 510(k) Re-submission for its CarpX™ Minimally Invasive Carpal Tunnel Device
March 8, 2020
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 1, 2020
PAVmed Adds EsoCure™ Esophageal Ablation Device with Patented Caldus™ Technology to Commercial Product Pipeline
February 17, 2020
U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test
February 10, 2020
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
January 12, 2020
PAVmed Subsidiary Lucid Diagnostics Announces Commercial Launch of EsoGuard Esophageal DNA Test
December 18, 2019
PAVmed Provides Update on CarpX™ Clinical Safety Study
December 12, 2019
PAVmed Reports Third Quarter 2019 Financial Results and Provides Business Update
November 20, 2019
PAVmed’s PortIO™ Intraosseous Infusion System Achieves Multiple Milestones
November 6, 2019
PAVmed to Hold Business Update Conference Call on November 21, 2019
November 5, 2019
PAVmed Reports Fourth Quarter 2018 Financial Results and Provides Business Update
April 3, 2019